- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 4 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| Di | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| Di | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 468 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| Di | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Examining the Future: Journey Medical's Earnings Outlook | 2 | Benzinga.com | ||
| 07.08. | Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11 | 3 | GlobeNewswire (USA) | ||
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025 | 1 | GlobeNewswire (USA) | ||
| 14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
| 14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
| 24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch | ||
| 09.06. | Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV | 2 | GlobeNewswire (USA) | ||
| 15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 15.05. | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
| 15.05. | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
| 14.05. | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 121 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,535 | +0,14 % | Pfizer und BioNTech: Gegenwind aus den USA - die Details | Die US-Arzneimittelbehörde FDA erwägt, die Notfallzulassung des Covid-Impfstoffs von Pfizer und dem Partner BioNTech für gesunde Kinder unter fünf Jahren zu widerrufen. Dies bestätigte der US-Pharmakonzern... ► Artikel lesen | |
| GILEAD SCIENCES | 101,22 | +0,08 % | GILEAD SCIENCES: Ausbruch wird möglich. | Die Aktie des kalifornischen Biotechunternehmens steht nach kräftiger Erholung nun am Niveau des vor zehn Jahren markierten Allzeithochs. Analysten von BofA Securities schätzen die Chance für einen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 335,45 | -0,07 % | VERTEX - Big-Picture-Kaufzone erreicht! | ||
| EYEPOINT PHARMACEUTICALS | 9,160 | -3,44 % | Mizuho hebt Kursziel für EyePoint Pharmaceuticals auf 28 US-Dollar an | ||
| ROCKET LAB | 37,800 | -0,53 % | Rocket Lab USA (RKLB) Acquires Geost to Eye National Security Programs | ||
| ASTRIA THERAPEUTICS | 6,000 | +2,56 % | Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress | ||
| OPKO HEALTH | 1,153 | -1,15 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 133,00 | +3,10 % | LIGAND PHARMACEUTICALS INC - 8-K, Current Report | ||
| JAZZ PHARMACEUTICALS | 99,56 | -1,03 % | BofA Securities raises Jazz Pharmaceuticals stock price target on Modeyso potential | ||
| ROYALTY PHARMA | 31,600 | +1,74 % | Dividendenbekanntmachungen (15.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2489 EUR ALBEMARLE CORPORATION PREF... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,235 | -0,35 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors | CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of Daniel Curran, MD, to its Board of... ► Artikel lesen | |
| TG THERAPEUTICS | 23,780 | -0,83 % | TG THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CORBUS PHARMACEUTICALS | 8,000 | +0,63 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals... ► Artikel lesen | |
| CATALENT | 59,93 | 0,00 % | GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent | Upstream phase of LUMEVOQ manufacturing process successfully transferred
Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and... ► Artikel lesen | |
| TALPHERA | 0,356 | -2,20 % | Talphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update | New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 6,940 Euro und damit -4,41 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.